Daiichi Sankyo (OTCMKTS:DSNKY) Cut to Strong Sell at Zacks Research

Daiichi Sankyo (OTCMKTS:DSNKY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday, Zacks reports.

Separately, Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Daiichi Sankyo presently has an average rating of “Reduce”.

Daiichi Sankyo Trading Down 0.1%

Shares of OTCMKTS:DSNKY opened at $17.90 on Tuesday. The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $27.50. The business has a 50 day moving average of $17.79 and a two-hundred day moving average of $17.16. The company has a market capitalization of $33.35 billion, a PE ratio of 20.81, a PEG ratio of 1.91 and a beta of -0.11.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, analysts forecast that Daiichi Sankyo will post 0.93 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.